portal hypertension
Conditions
Interventions
Group A:Oral losartan by 25mg/d of the initial dose, three days latter alternate to 50mg/d
Group B:Oral propranolol by 20mg/d of initial dose
then, progressively increase 10mg/d, max dose 120mg/d or rest heart rate reduced to the 75% of fundamental rate, or no less than 55/min
Sponsors
Department 1 of Infectious Diseases, 302 Hospital of P.L.A
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Consistent with cirrhosis qualification of "prophylaxis and treatment of virus hepatitis" made by Chinese Medical Association in 2000.diagnosed varicosity by B us\CT\endoscopy\MRI (Child B/C or red colour sign+), partner follow-up; 2. 18-65years, male or female; 3. Signed informed consent; 4. Had not receipted other therapy of portal hypertension.
Exclusion criteria
Exclusion criteria: 1. Recept TIPPS\bypass\disconnection; 2. Desire to recept TIPPS\bypass\disconnection; 3. Complic with hepatic encephalopathy\hepatorenal syndrome\liver cancer; 4. Complic with contraindication of beta-receptor blocking pharmacon; 5. Complic with contraindication of ARB; 6. Women in lactation or gestation period; 7. Anaphylactic predisposition; 8. Alcohol or drug abusing or other tendency to interference follow-up; 9. Partaking in other drug trial; 10. Advanced disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HARI\SpAR\HAPI\SpAPI\PHI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stiffness with fibrosca; | — |
Countries
China
Contacts
Public ContactMin Zhao
Outcome results
None listed